Enzo Biochem, Inc.
Enzo Biochem, Inc. (ENZ) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Enzo Biochem, Inc. (ENZ), featuring income statements, balance sheets, and cash flow data.
Enzo Biochem, Inc. (ENZ) Income Statement & Financial Overview
Explore comprehensive income reports for Enzo Biochem, Inc. ENZ, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $7.33M | $6.21M | $7.53M | $8.02M |
| Cost of Revenue | $3.55M | $3.68M | $4.31M | $4.29M |
| Gross Profit | $3.79M | $2.53M | $3.22M | $3.73M |
| Gross Profit Ratio | $0.52 | $0.41 | $0.43 | $0.47 |
| R&D Expenses | $479000.00 | $562000.00 | $607000.00 | $605000.00 |
| SG&A Expenses | $4.56M | $4.88M | $7.80M | $4.48M |
| Operating Expenses | $5.39M | $6.15M | $5.78M | $5.08M |
| Total Costs & Expenses | $8.94M | $9.84M | $10.09M | $9.37M |
| Interest Income | $0.00 | $0.00 | $942000.00 | $726000.00 |
| Interest Expense | $0.00 | $0.00 | $197000.00 | $0.00 |
| Depreciation & Amortization | $318000.00 | $319000.00 | $398000.00 | $337000.00 |
| EBITDA | -$1.28M | -$2.85M | -$2.22M | -$1.01M |
| EBITDA Ratio | -$0.18 | -$0.46 | -$0.29 | -$0.13 |
| Operating Income | -$1.60M | -$3.07M | -$2.67M | -$1.35M |
| Operating Income Ratio | -$0.22 | -$0.49 | -$0.35 | -$0.17 |
| Other Income/Expenses (Net) | $354000.00 | $0.00 | $1.52M | -$780000.00 |
| Income Before Tax | -$1.25M | -$3.07M | -$1.15M | -$2.13M |
| Income Before Tax Ratio | -$0.17 | -$0.49 | -$0.15 | -$0.27 |
| Income Tax Expense | $287000.00 | $305000.00 | $0.00 | $889000.00 |
| Net Income | -$1.53M | -$3.38M | -$13.38M | -$3.02M |
| Net Income Ratio | -$0.21 | -$0.54 | -$1.78 | -$0.38 |
| EPS | -$0.03 | -$0.06 | -$0.26 | -$0.06 |
| Diluted EPS | -$0.03 | -$0.06 | -$0.26 | -$0.06 |
| Weighted Avg Shares Outstanding | $52.30M | $52.24M | $52.24M | $51.21M |
| Weighted Avg Shares Outstanding (Diluted) | $52.30M | $52.24M | $52.24M | $51.21M |
The company's financials show resilient growth, with revenue advancing from $8.02M in Q3 2024 to $7.33M in Q2 2025. Gross profit remained healthy with margins at 52% in Q2 2025 compared to 47% in Q3 2024. Operating income hit -$1.60M last quarter, sustaining a consistent -22% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.28M. Net income rose to -$1.53M, while earnings per share reached -$0.03. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan